Publications
Publications
Show Results For
- All HBS Web
(65)
- Faculty Publications (18)
Oncology
→
Page 1 of 18
Results
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
- July 2021 (Revised July 2022)
- Case
Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care
By: Robert S. Kaplan, Navraj S. Nagra and Syed S. Shehab
Dr. Andrea Pusic, breast cancer reconstruction surgeon, wants to extend outcomes measurement beyond traditional surgical metrics of infections, complications, and survival rates. The case describes her development of a new mobile phone app, which collects patients’... View Details
- Article
Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology
By: Palak Kundu, Olivia Jung, Luca F. Valle, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
“Near miss” events are valuable low-cost learning opportunities in radiation oncology as they do not result in patient harm and are more pervasive than adverse events that do. Near misses vary depending on the presence of a latent error of behavior or process, and the... View Details
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
- Article
Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology
By: Palak Kundu, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
Background
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
- December 2020 (Revised April 2021)
- Case
IBM Watson at MD Anderson Cancer Center
By: Shane Greenstein, Mel Martin and Sarkis Agaian
After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology... View Details
Keywords: Decision Making; Innovation Strategy; Knowledge Management; Knowledge Use and Leverage; Operations; Failure; Information Technology; Applications and Software; Health Care and Treatment; Product Development; Health Industry; Information Technology Industry; Technology Industry; United States; Houston; Texas
- Article
Psychological Safety and Near Miss Events in Radiation Oncology
By: Palak Kundu, Olivia Jung, Kathy Rose, Chonlawan Khaothiemsang, Nzhde Agazaryan, Amy C. Edmondson, Michael L. Steinberg and Ann C. Raldow
Background: Near miss events, defined as harm averted due to chance, are learning opportunities in radiation oncology. Psychological safety is a feature of a learning environment characterized by interpersonal risk taking. We examine the effects of near miss type and... View Details
- November 12, 2018
- Article
Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology
By: Richard G. Hamermesh and Kathy Giusti
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment... View Details
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details
Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States
- December 2013 (Revised February 2014)
- Supplement
Reinventing Brainlab (B)
By: Regina E. Herzlinger and Karol Misztal
The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details
- September 2012 (Revised March 2014)
- Case
Reinventing Brainlab (A)
By: Regina E. Herzlinger, Vincent Dessain and Karol Misztal
The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details
- September 2012
- Supplement
Intraoperative Radiotherapy for Breast Cancer (B)
By: Willy Shih
The intraoperative radiotherapy (IORT) business at Carl Zeiss Meditec had struggled with growth since the time of the (A) case. Though the unit had grown revenues in excess of 50% and had exceeded its EBIT target, it faced several key strategic choices. Should it... View Details
Keywords: Radiotherapy; Breast Cancer; Brachytherapy; Therapeutic Radiation; Oncology; Oncology Treatment Systems; Elekta AB; Varian Medical Systems; Xoft; Electronic Brachytherapy; Intraoperative Radiotherapy; Disruptive Innovation; Health Care and Treatment; Entrepreneurship; Technological Innovation; Growth and Development Strategy; Health Industry; Germany
- August 2012 (Revised August 2014)
- Case
Cancer Treatment Centers of America® (A)
By: Regina E. Herzlinger and Natalie Kindred
Cancer Treatment Centers of America (CTCA), a U.S. network of four privately owned oncology focused factory hospitals, was weighing options for growth. CTCA was entirely cancer focused and specialized in treating patients with complex and advanced-stage cancers, who... View Details
Keywords: Cancer; Cancer Treatment; Health Care; Healthcare; Accountability; Outcomes; Outcomes Measurement; Outcomes Reporting; Hub And Spoke Cancer Care; Hub And Spoke; Hub-and-spoke; Focused Factory; Mission and Purpose; Private Ownership; For-Profit Firms; Health Disorders; Medical Specialties; Policy; Business Model; Expansion; Decision Choices and Conditions; Advertising; Health Care and Treatment; Innovation and Invention; Health Industry; United States
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details